Acceleware Recognized by University of Madison-Wisconsin for Aiding in Breast Cancer Research
Calgary, Alberta – October 4, 2007 – Acceleware Corp. (TSXV: AXE) a leading developer of high-performance computing (HPC) solutions, today announced its recognition from the University of Wisconsin-Madison for making solid progress in investigating new ways to detect and treat early-stage breast cancer .
Dr. Susan Hagness and her multi-disciplinary team of scientists at the University of Wisconsin-Madison are investigating the use of ultra short pulses of low-power electromagnetic waves to produce three-dimensional diagnostic images of the breast, and higher-power waves to focus energy at the site of a tumor to treat the cancer. The imaging technology has a potential to detect cancer through harmless scans of the breast and provide diagnostic information that is complementary to X-ray mammography.
“Our breast imaging technology incorporates algorithms such as inverse scattering solutions, which are tremendously computer-intensive," said Dr. Hagness, University of Wisconsin-Madison. "Acceleware’s hardware solution enables us to complete our computations and generate images in hours instead of days. Minimizing the time required to generate complex images is fundamental to helping save lives and reduce suffering."
Acceleware's hardware acceleration platform utilizes the power of NVIDIA GPU computing solutions to dramatically increase the speed of the sophisticated computations required by breast imaging technology, thus decreasing time to treatment for people with positive diagnosis of breast cancer.
“Acceleware is committed to creating innovative technology which will advance research in many areas,” said Ryan Schneider, CTO of Acceleware. “Using Acceleware’s hardware application platform we are able to significantly increase the speed of the complex computations required by this technology. We believe this change alone will give researchers more time to devote to the bigger problem at hand hence developing more life-saving applications.”
Facts on Breast Cancer DetectionThe key to surviving breast cancer is early detection. Studies have shown that smaller tumor size discovered by early detection accounts for 61 percent improvement in breast cancer survival rates when it has not spread beyond the breast, and 28 percent when it has spread modestly beyond the breast, according to the Memorial Sloan-Kettering Cancer Center study, published in American Cancer Society’s online publication 'Cancer,' August, 2005.
The World Health Organization estimates that 1.2 million women globally were diagnosed with breast cancer in 2006. It is the most common form of cancer diagnosis, and second leading cause of cancer deaths among women, according to: http://ezinearticles.com/index.php?Breast-Cancer-Statistics&id=352970. Breast cancer is not restricted to women; thousands of men are diagnosed with breast cancer annually; it is statistically far less prevalent in men. A woman's chance of developing breast cancer during her lifetime is about 1 in 7.
Acceleware specializes in the development and marketing of special purpose software/hardware acceleration products used to reduce design simulation and data processing run-times of high-performance computing (HPC) applications such as cell-phone design, seismic data processing, printed circuit board design, drug discovery, photonic/communications devices design, oil reservoir simulation, lithography mask design, bio-medical imaging and others.
Acceleware products are distributed by computer-aided design (CAD) and computer-aided engineering (CAE) software companies to end-users at the world's largest organizations in a wide range of industries. In each vertical market, Acceleware's third-generation board-level and engineering workstation products accelerate simulation and processing algorithms by a factor of 10 times or more, on average, reducing runtimes from multiple hours to minutes. Acceleware is a public company on Canada's TSX Venture Exchange under the trading symbol AXE.
For more information on Acceleware, visit www.acceleware.com.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.